鷺燕醫藥(002788.SZ):在廈門、亳州設有中藥飲片廠,目前生產的中藥飲片品種已基本覆蓋主要品種
格隆匯6月27日丨鷺燕醫藥(002788.SZ)近期在接待機構調研時表示,公司聚焦於中藥飲片的生產與銷售,在廈門、亳州都設有中藥飲片廠,目前生產的中藥飲片品種已基本覆蓋主要品種。同時,公司下屬智慧煎藥中心承接了廈門、福州等地市部分醫院等的中醫藥方劑的調配、煎煮及配送工作。此外,公司正在全力推進鷺燕亳州中醫藥產業園項目的建設工作,致力於打造面向全球的高質量全品種的中藥飲片生產、銷售、檢測平台。未來公司將加大研發投入和技術升級,豐富產品品種,提升產能規模,推進產業鏈的延伸。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.